Biotech News

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Celldex Therapeutics (CLDX)Celldex TherapeuticsClinical readout

Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met. While some benefit from barzolvolimab treatment was observed, these improvements did not meet the Company’s internal hurdle rate for continued development. Data suggest that while mast cells contribute to AD, they are not a primary driver of the disease. Based on these results, Celldex is discontinuing development in AD. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile.

Related news

CLDXCelldex Therapeutics2026-09-22 10:58 EST

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

IMMPImmutep Limited2026-11-19 00:12 EST

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

REGNRegeneron Pharmaceuticals2026-11-12 22:00 EST

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

ZURAZura Bio2026-11-09 12:00 EST

Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa

CABACabaletta Bio2026-11-08 15:00 EST

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

IFRXInflarx NV2026-11-06 12:30 EST

InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

TLSATiziana Life Sciences2026-11-02 12:00 EST

Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Celldex Therapeutics

Mast Cell-Targeted Immunology Company Celldex Therapeutics is developing barzolvolimab, a KIT-targeting antibody for mast cell-driven diseases. Because KIT signaling is central to mast cell survival and function, the therapy is intended to provide deeper disease modification than symptom-focused treatment alone. Barzolvolimab in...

Recent company news

Stock data

Close
27.96 USD
Market cap
2.27B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States